ALS Group USA, Corp – FDA 483, Jan 25, 2019
An FDA inspection of BioScreen Testing Services Inc in Torrance, CA, a control testing laboratory, revealed significant deficiencies in their quality system. Observations included a lack of software validation documentation, inadequate investigations into out-of-specification results and failures, incomplete laboratory records due to discarded original documentation, and failure to follow written production and process control procedures. These issues indicate a systemic breakdown in maintaining data integrity and ensuring product quality.
ID · 0724040e-144f-4a1a-9490-c9fa043695b0
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.